#188: Dom D'Agostino on Disease Prevention, Cancer, and Living Longer

Episode Summary

Executive Summary: Tim Ferriss and Dom D’Agostino discuss ketogenic diets as a therapeutic tool, especially for aggressive cancers like glioblastoma, and how ketosis can complement radiation, chemotherapy, fasting, hyperbaric oxygen, and exercise. Dom also addresses fasting, muscle retention, APOE4, cheat meals, metformin, carb backloading, and the safety of exogenous ketones, emphasizing individualized use and the importance of achieving a meaningful metabolic state rather than treating keto as a universal cure.

Main Topics: Ketogenic diet and cancer therapy (Priority: 5/5): Dom argues keto is not superior to chemo for all cancers, but can be a powerful adjuvant—especially for highly glycolytic, aggressive cancers like glioblastoma and metastatic disease. Metabolic zone and glucose-ketone index (Priority: 5/5): He repeatedly emphasizes targeting a glucose-ketone index around 1 as a practical marker of therapeutic ketosis for cancer prevention and treatment support. Fasting, muscle retention, and supplementation (Priority: 4/5): The discussion covers how to enter ketosis without supplements, how fasting affects lean mass, and how branched-chain amino acids, 5-HTP, MCTs, and ketones may help. Hyperbaric oxygen plus ketosis (Priority: 4/5): Dom explains why ketosis may improve the safety and efficacy of hyperbaric oxygen therapy, especially by reducing CNS oxygen toxicity risk and stressing tumor cells. Performance, endurance, and carb backloading (Priority: 3/5): He addresses keto adaptation for endurance and glycolytic training, noting that adaptation takes months and that carb backloading can work if carefully controlled. APOE4, longevity, and metformin (Priority: 3/5): Dom discusses APOE4-related inflammation, the potential role of nutritional ketosis and fasting, and the uncertain but interesting longevity effects of metformin. Safety of exogenous ketones (Priority: 3/5): He defends ketone salts and related products as generally safe based on widespread use and published data, while noting therapeutic claims still need clinical trials.

Key Arguments: Ketogenic diets do not beat chemotherapy for all cancers, but they may significantly improve outcomes as an adjuvant in aggressive, glycolytic tumors. Glioblastoma and metastatic cancers are the main targets because they exhibit a Warburg-like, glucose-dependent phenotype. Radiation may work better in ketosis because reduced glycolysis and pentose phosphate pathway activity can weaken tumor antioxidant defenses. A glucose-ketone index near 1 is presented as a useful therapeutic target for cancer-related ketosis. Fasting can support autophagy and immune vigilance, but excessive fasting/calorie restriction may suppress immunity. Lean mass loss during fasting can be mitigated somewhat with branched-chain amino acids, and fasting ketosis is protein-sparing. Ketosis may improve hyperbaric oxygen therapy by reducing seizure risk and increasing oxidative stress selectively in tumors. Keto adaptation for athletic performance takes time—often months—and short studies may underestimate benefits because athletes are not fully adapted. APOE4 carriers may benefit more from true carbohydrate restriction and ketosis than from MCT-only interventions. Metformin may mimic some calorie restriction signaling, but its long-term longevity benefit remains unproven and side effects matter. Exogenous ketone salts appear broadly safe in practice, with GI upset being the main reported issue, though therapeutic use still needs formal trials.

Data Points: Glucose-ketone index target: ~1 - Dom says this is the ideal therapeutic zone where blood glucose and ketones are roughly equal. Ketosis duration for adaptation: 3 to 6 months - He says full keto adaptation for performance can take months, especially for athletes. Hyperbaric oxygen protocol in preclinical model: 2.5 atmospheres, 3x/week - Used in Dom’s preclinical cancer model. Lower starting hyperbaric dose for brain tumor patients: 1.5 atmospheres for 45–60 minutes - Suggested to reduce CNS oxygen toxicity risk. Wound-healing hyperbaric protocol: ~2 atmospheres, 5x/week - Described as a common clinical pattern for wound care. Cancer types in pilot ketogenic diet trial: 16 patients with advanced cancer - Pilot trial cited for quality-of-life outcomes. Cancer types in that pilot: ovarian, breast, sarcoma, osteosarcoma, esophageal, pancreatic, thyroid, colon, endometrial, lung, stomach - Varied cancers included in the quality-of-life study. High glucose threshold mentioned: >140 mg/dL - Dom warns repeated spikes above this may contribute to beta-cell loss. Cancer risk concern threshold: >160 mg/dL - He says repeated spikes around this level may increase cancer risk over time. Stroke risk association: 25% increase per 1 mmol/L rise in post-meal blood sugar - Cited as a documented risk relationship. Carb backloading amount: 100–200 g carbs - Dom says this may be enough post-workout for him, even though he previously used more. Earlier carb backloading amount: ~350 g carbs - He says he once ramped up to this level after hard workouts. Metformin dose discomfort threshold: >2 g - He reports GI discomfort above this amount. Ketone salt use estimate: ~10 million doses - Dom cites widespread consumption of DL beta-hydroxybutyrate salts worldwide. Fat oxidation in adapted athletes: ~2x more fat - He references long-term keto-adapted athletes burning roughly twice as much fat at rest/training.

Pivotal Quotes: "Does the ketogenic diet beat chemo for all cancers? And I would say absolutely not." — Dom D’Agostino: Direct answer to the central cancer-therapy question. "The ketogenic diet, when properly administered, can dramatically enhance the efficacy of standard of care." — Dom D’Agostino: His core thesis on keto as an adjuvant in aggressive cancers. "The limitation of the therapeutic potential of hyperbaric oxygen therapy is the limitation of the dose to avoid CNS oxygen toxicity." — Dom D’Agostino: Explains why ketosis may make hyperbaric oxygen safer and more usable.

Implications: Listeners should view keto as a targeted metabolic tool, not a universal cure. The biggest near-term opportunities are cancer adjuvant therapy, performance optimization, and individualized metabolic health strategies, but many claims still need stronger clinical validation.